Skip to Main Content

Aurinia Pharmaceuticals won approval from the Food and Drug Administration on Friday evening to market a new medicine for patients with lupus nephritis, a serious autoimmune kidney disease. It’s good news for patients, but the nature of the approval also makes it especially good news for Aurinia and investors.

While the approval of the new drug, called Lupkynis, was expected, the FDA allowed Aurinia to include proprietary dosing instructions in its prescribing label. The dosing instructions help physicians tailor Lupkynis treatment for lupus nephritis patients, but they also strengthen and extend the drug’s patent protection.

advertisement

Lupkynis is the first commercial product developed successfully by Aurinia, a drug maker founded in 1993 and based near Vancouver, Canada.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.